분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2007-06-04 18:47:33 , Hit : 4478
 Genetically Modified Stem Cells May Have Therapeutic Application to X-SCID

A study demonstrating therapeutic utilization of human stem cells, including potential application to X-linked Severe Combined Immunodeficiency (XSCID or “Bubble-Boy” disease) was presented today at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle.

X-linked Severe Combined Immunodeficiency (XSCID) is a rare genetic disease caused by defects in an essential immune hormone receptor called the common gamma chain (γc), found on the surface of lymphocytes and other immune blood cells. Patients with XCID have immune cells that lack this receptor and both fail to develop properly, as well as do not function normally to protect patients against infections.

A team of scientists led by Dr. Luigi Naldini from the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milan and Sangamo BioSciences Inc., Richmond, CA, are developing a novel approach to genetically modify embryonic and tissue stem cells for therapeutic use. This approach can potentially be applied to many diseases, including X-SCID.

Using technology developed by Sangamo, the scientists showed gene correction or precise addition of a gene in human stem cells at unprecedented levels.

“This is a significant advance for the potential therapeutic use of stem cells,” says Dr. Angelo Lombardo, lead author of the study. “Stem cells are the body’s natural resource for regeneration and repair and the ability to efficiently insert a therapeutic gene in a predetermined location or to correct a mutated gene in a patient’s stem cells may enable us to provide a long term solution for many genetic diseases. The powerful combination of Sangamo’s ZFN™ technology and our highly efficient viral delivery platform was the key factor for obtaining unprecedented gene modification efficiency in these therapeutically important cells”.

Using this approach, an inherited mutation in a gene can be directly corrected or modified in a cell or a new copy of a gene can be added into the genome at a specific and predetermined site. This is a significant advance over traditional approaches that rely on the random insertion of a new copy of a gene to cells to restore the missing function of an inherited mutant gene. In fact, despite the successful outcome of gene therapy reported in many SCID patients, random insertion of genes into the cellular genome may in some circumstances lead to serious adverse effects due to altered expression of the therapeutic gene or its neighboring genes at the insertion site.

In contrast, Dr. Naldini’s study demonstrates that ZFN-mediated gene editing can be used to correct mutations in the IL-2R gamma gene, the defective gene in X-linked SCID, and to add a therapeutic gene to a pre-determined ‘safe-harbor’ site in the genome of both human hematopoietic progenitors and human ES cells with high efficiency. This ‘safe-harbor site’ was selected by the investigators for its capacity to allow efficient expression of the therapeutic gene and to tolerate an insertion event without adverse effects.

ZFN-mediated gene editing overcomes some major limitations of standard gene therapy approaches and potentially provides a unique means to treat disease with HSCs and ES cells in a safe and effective manner.

The scientists used novel designer proteins, named zinc finger DNA-binding protein nucleases (ZFN), that were developed at Sangamo BioSciences. ZFN can be engineered to specifically cut DNA at a chosen site.

Dr. Naldini’s team exploited the high infectious capacity of lentiviral vectors derived from HIV to express ZFN and provide the template DNA for gene correction in target cells. When they introduced ZFN into target cells with an appropriately designed donor DNA molecule that encodes the correct gene sequence, the DNA break was repaired in a natural process by the cell’s DNA-repair machinery leading to correction of the mutation or the preci







1047   Gene therapy using HIV helps children with fatal diseases, study says  이성욱 2013/07/16 2018
1046   Gene therapy 'could be used to treat blindness'Pallab Ghosh  이성욱 2014/01/23 1748
1045   Gene therapy 'hope' on impotence  이성욱 2007/06/04 5005
1044   Gene-therapy hope for β-thalassaemia patients  이성욱 2010/09/21 2483
1043   Genetic circuit kills cancer cells using unique microRNAs  이성욱 2011/09/08 4931
1042   Genetic variant linked to development of liver cancer in hepatitis C virus carriers  이성욱 2011/12/03 2622
1041   Genetically Altered Stem Cells Generate Engineered Cartilage  이성욱 2014/02/22 2057
1040   Genetically Engineered Pigs May Fly as Cancer Models  이성욱 2016/05/17 936
  Genetically Modified Stem Cells May Have Therapeutic Application to X-SCID  이성욱 2007/06/04 4478
1038   Genetically 'edited' fruit could soon hit supermarket shelves  이성욱 2014/08/15 1331
1037   Genomics: The single life  이성욱 2012/11/06 2088
1036   Genzyme, Voyager Launch Up-to-$845M Gene Therapy Collaboration  이성욱 2015/02/14 1277
1035   Giant viruses open Pandora's box  이성욱 2013/07/26 2026
1034   Giants of Circadian Biology Win Nobel Prize  이성욱 2017/10/03 519
1033   Gilead Drug Combination Cures Hepatitis C in HIV Patients  이성욱 2014/07/22 1654
1032   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1075
1031   Gilead Licenses Hepatitis Therapy in India Amid Price Criticism  이성욱 2014/09/17 1710
1030   Gilead secures approval in Japan for Sovaldi to treat genotype 2 chronic HCV  이성욱 2015/03/31 988
1029   Gilead seeks FDA OK for game-changing hepatitis C drug  이성욱 2013/04/10 2115
1028   Gilead submits fixed-dose combination ledipasvir/sofosbuvir HCV tablet for FDA approval  이성욱 2014/02/12 2345

[이전 10개] [1]..[11] 12 [13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN